All News

26 September 2007

New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical ResponseAntibodies

26 September 2007

Abbott and Eisai submit application for adalimumab, the only fully human monoclonal anti-TNFalpha antibody, to treat psoriasisAntibodies

22 September 2007

Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European UnionAntibodies

21 September 2007

Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce AmputationsAntibodies

21 September 2007

ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical TrialsAntibodies

21 September 2007

FDA Approves Expanded Labeling for CampathÂ® to Include First-line Treatment for Leading Form of Adult LeukemiaAntibodies

19 September 2007

Antitope Announces Research Agreement with Fraunhofer Institute for Cell Therapy and ImmunologyAntibodies

19 September 2007

LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 TherapiesAntibodies

14 September 2007

Genmab Provides Insights into IgG4 AntibodiesAntibodies

14 September 2007

Genmab Discloses Target and Development Plans for HuMax-InflamAntibodies

14 September 2007

DAHANCA Initiates Head and Neck Cancer Study with Genmab’s HuMax-EGFrAntibodies

13 September 2007

XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory DiseasesAntibodies

12 September 2007

Astellas Initiates Phase II Clinical Trials for Immunosuppressant, ASP0485Antibodies

11 September 2007

Merck: Erbitux Phase III Study – FLEX Increases Overall Survival in First-line Treatment of Non-Small Cell Lung CancerAntibodies

11 September 2007

Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid ArthritisAntibodies

8 September 2007

Genmab announces encouraging preclinical data for OfatumumabAntibodies

8 September 2007

ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402Antibodies

8 September 2007

Ablynx and Boehringer Ingelheim announce major global strategic alliance to discover, develop and commercialise novel nanobody(R) therapeuticsAntibodies

6 September 2007

Access and Somanta Announce New Data on Angiolix(R) Humanized Monoclonal AntibodyAntibodies

6 September 2007

Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic AntibodiesAntibodies

6 September 2007

Medarex Announces Extension of Broad Antibody Development Relationship with CentocorAntibodies

5 September 2007

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization ProcessAntibodies

5 September 2007

YM BioSciences Announces positive preliminary results from Phase I/II lung cancer trial of nimotuzumab combined with radiationAntibodies

4 September 2007

Merck Applies to Extend Use of Erbitux(R) for 1st-Line Colorectal CancerAntibodies

31 August 2007

YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancerAntibodies

30 August 2007

Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer PatientsAntibodies

30 August 2007

Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient EnrollmentAntibodies

29 August 2007

XOMA Licenses Antibody Technology to PfizerAntibodies

29 August 2007

Baxter and the Alzheimer’s Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients with Alzheimer’s DiseaseAntibodies

25 August 2007

Genentech announces resubmission of supplemental Biologics License Application for Avastin in combination with Paclitaxel for first-line metastatic breast cancerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Mesothelin-Targeted Immunotherapy Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review